304 related articles for article (PubMed ID: 8254956)
1. [Clinical usefulness of tumor markers in breast cancer].
Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
[TBL] [Abstract][Full Text] [Related]
2. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
Kaneko Y; Imoto S; Kasakura S
Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of tumor marker CA15-3 in breast cancer].
Kikuchi K; Uematsu Y; Takada Y; Kurihara E; Suito T; Fujisaki M; Takahashi R; Tamura T
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3095-100. PubMed ID: 3479052
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
5. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
6. [Tumor markers in breast cancer].
Harada Y; Ohuchi N; Ishida T; Ohnuki K
Gan To Kagaku Ryoho; 2001 Jul; 28(7):1035-40. PubMed ID: 11478135
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of tumor markers in breast cancer patients].
Ito T; Tanaka S; Ban K; Sakai N; Oshita H; Oiwa T; Kanno A; Kashizuka T
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907
[TBL] [Abstract][Full Text] [Related]
8. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
[TBL] [Abstract][Full Text] [Related]
9. [Tumor markers in the diagnosis and prognosis of breast cancer].
Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
[TBL] [Abstract][Full Text] [Related]
10. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M
Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752
[TBL] [Abstract][Full Text] [Related]
11. [MSA--a new sensitive tumor marker in breast carcinoma].
Zahm DM; Greinke C; Nöschel H
Zentralbl Gynakol; 1996; 118(12):659-64. PubMed ID: 9082702
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.
Tondini C; Hayes DF; Gelman R; Henderson IC; Kufe DW
Cancer Res; 1988 Jul; 48(14):4107-12. PubMed ID: 3164256
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA].
Okamura Y; Takatsuka Y; Katoh T; Tsumura I; Kobayakawa K; Kawahara T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1279-85. PubMed ID: 2069399
[TBL] [Abstract][Full Text] [Related]
14. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
Nakamura T; Kimura T; Umehara Y; Suzuki K; Okamoto K; Okumura T; Morizumi S; Kawabata T
Surg Today; 2005; 35(1):19-21. PubMed ID: 15622458
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer.
Ogawa Y; Ishikawa T; Ikeda K; Nakata B; Sawada T; Ogisawa K; Kato Y; Hirakawa K
Clin Cancer Res; 2000 Oct; 6(10):4069-72. PubMed ID: 11051258
[TBL] [Abstract][Full Text] [Related]
16. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
17. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.
Nakata B; Takashima T; Ogawa Y; Ishikawa T; Hirakawa K
Br J Cancer; 2004 Aug; 91(5):873-8. PubMed ID: 15280913
[TBL] [Abstract][Full Text] [Related]
18. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
19. Midkine in plasma as a novel breast cancer marker.
Ibusuki M; Fujimori H; Yamamoto Y; Ota K; Ueda M; Shinriki S; Taketomi M; Sakuma S; Shinohara M; Iwase H; Ando Y
Cancer Sci; 2009 Sep; 100(9):1735-9. PubMed ID: 19538527
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen.
Fujino N; Haga Y; Sakamoto K; Egami H; Kimura M; Nishimura R; Akagi M
Jpn J Clin Oncol; 1986 Dec; 16(4):335-46. PubMed ID: 3467106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]